Clinical Hematology Review: Highlights From NEJM, Blood and JCOClinical Oncology NewsUnlike rituximab (Rituxan, Biogen Idec/Genentech), obinutuzumab has no black box warnings. True False; True or False. In a Phase II study published in The New England …
Anti-CD20 Antibody + Chemo Benefits CLL With ComorbidityDoctors LoungeFor patients with previously untreated chronic lymphocytic leukemia and coexisting conditions, combining an anti-CD20 antibody (rituximab or obinutuzumab) with chemotherapy is associ…
Stanford shares in $540 million gift from Ludwig Cancer ResearchLab Manager MagazineJust recently, Weissman and his colleagues reported in the journal Science that this protein works particularly well when used in combination with other known anti-canc…
|
J&J’s Imbruvica tops Arzerra in phase III trial
PMLiVE … is already approved as a second-line therapy for CLL – making sales of £56m in the first nine months of 2013 – although growth has been fairly slow because the product has struggled to displace Roche’s Rituxan/MabThera (rituximab) in these patients. |
|
Billionaire’s Institute Donates $90 Million to Stanford
Patch.com Just recently, Weissman and his colleagues reported in the journal Science that this protein works particularly well when used in combination with other known anti-cancer agents, such as rituximab (a lymphoma drug) and trastuzumab, also known as … |
Induction chemotherapy did not improve outcomes in HNSCCHealio… on the evolution of therapy-related acute myeloid leukemia. Head-to-head comparison of obinutuzumab plus chlorambucil vs. rituximab plus chlorambucil in patients with chronic lymphocytic…
Stanford University NewsStanford shares in $540 million gift from Ludwig Cancer ResearchStanford University NewsJust recently, Weissman and his colleagues reported in the journal Science that this protein works particularly well when used in combinatio…
Drug Discovery & Development |
PIXUVRI® (pixantrone) Receives Positive Final Appraisal Determination from …
MarketWatch … showing PIXUVRI’s cost effectiveness and recommended the treatment as an option for certain people with histologically confirmed aggressive B-cell NHL who have previously received rituximab and are receiving PIXUVRI as a third- or fourth-line … UK’s NICE Issues Final Appraisal Determination on CTI Lymphoma DrugDrug Discovery & Development Cell Therapeutics Inc (CTIC): Is Cell Therapeutics Turning Over A New Leaf In …Seeking Alpha |
Cell Therapeutics Inc (CTIC): Is Cell Therapeutics Turning Over A New Leaf In …Seeking AlphaThe company is currently accruing patients into this study, which will compare Pixantrone and rituximab with gemcitabine and rituximab in the setting of aggre…
Drug Discovery & Development |
UK’s NICE Issues Final Appraisal Determination on CTI Lymphoma Drug
Drug Discovery & Development … reviewed CTI’s updated data analysis showing Pixuvri’s cost effectiveness and recommended the treatment as an option for certain people with histologically confirmed aggressive B-cell NHL who have previously received rituximab and are receiving … PIXUVRI® (pixantrone) Receives Positive Final Appraisal Determination from …MarketWatch |